SGRZ yields 2000000.00% · ABBV yields 3.06%● Live data
📍 SGRZ pulled ahead of the other in Year 1
Combined, SGRZ + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SGRZ + ABBV for your $10,000?
Stonepath Group Inc., a third-party logistics company, provides transportation and logistics services worldwide. The company offers various supply chain solutions to a diverse client base, including manufacturers, distributors, and retail chains. Its transportation services include air and ocean freight forwarding, distribution, customs brokerage, consulting services, shipment tracking between pickup and delivery, and other customized management services. Stonepath Group co-ordinates the movement of raw materials, supplies, components, and finished goods for its customers throughout North America and internationally. The company also provides warehousing and distribution services in North America, and offers customs clearance and bonded warehousing services in the international markets. In addition, it provides contract logistics, global project management, order fulfillment, and inventory control services. As of March 31, 2006, the company operated a network of offices in 21 major metropolitan areas in North America, 17 locations in the Asia Pacific region, 3 locations in Brazil, and 1 location in Europe, as well as a network of independent agents and service partners worldwide. The company was formerly known as Net Value Holdings and changed its name to Stonepath Group Inc. in October 2000. The company was incorporated in 1998 and is based in Seattle, Washington. On May 8, 2007, an involuntary petition for bankruptcy protection was filed by Spherion Corporation, Custom Transfer Incorporated, and Overbye Transport Incorporated against Stonepath Group Inc. under Chapter 7 liquidation with the U.S. Bankruptcy Court for the District of Delaware.
Full SGRZ Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.